 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Eliminationhalf-life | 12.5 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.126.841 |
| Chemical and physical data | |
| Formula | C22H22N2O6 |
| Molar mass | 410.426 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Darusentan (LU-135252; HMR-4005) is anendothelin receptor antagonist.[1] Gilead Colorado, a subsidiary ofGilead Sciences,[2] under license fromAbbott Laboratories, is developing darusentan for the potential treatment of uncontrolledhypertension.
In June 2003,Myogen licensed the compound from Abbott for its application in the cancer field.[3]
In May 2007, a randomized, double-blind, active control, parallel assignment, safety and efficacyphase III trial was initiated in subjects who had completed the maintenance period of the DAR-312 study, but was terminated because the study did not reach its primary endpoints.[4]
 | Thisdrug article relating to thecardiovascular system is astub. You can help Wikipedia byexpanding it. |
 | Thisantineoplastic orimmunomodulatorydrug article is astub. You can help Wikipedia byexpanding it. |